Invited Review Free radicals and the pathobiology of brain dopamine systems

[1]  A. Schapira,et al.  Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  C. Vorhees,et al.  Effect of methamphetamine on glutamate‐positive neurons in the adult and developing rat somatosensory cortex , 1996, Synapse.

[3]  B. Robinson,et al.  Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. , 1996, The Journal of clinical investigation.

[4]  C. Epstein,et al.  Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice , 1996, Brain Research.

[5]  C. Epstein,et al.  Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn‐superoxide dismutase transgenic mice , 1995, Synapse.

[6]  M. Naoi,et al.  N-methyl(R)salsolinol produces hydroxyl radicals: involvement to neurotoxicity. , 1995, Free radical biology & medicine.

[7]  M. Zigmond,et al.  Estimating Hydroxyl Radical Content in Rat Brain Using Systemic and Intraventricular Salicylate: Impact of Methamphetamine , 1995, Journal of neurochemistry.

[8]  C. Olanow,et al.  Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.

[9]  C. Olanow,et al.  Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.

[10]  S. Daniel,et al.  Glutathione‐related enzymes in brain in Parkinson's disease , 1994, Annals of neurology.

[11]  W Slikker,et al.  MPTP‐induced oxidative stress and neurotoxicity are age‐dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels , 1994, Synapse.

[12]  J. O'Callaghan,et al.  Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. , 1994, The Journal of pharmacology and experimental therapeutics.

[13]  D. Sulzer,et al.  Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  S. Snyder,et al.  Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. , 1994, Science.

[15]  C. Epstein,et al.  Rapid Communication: Attenuation of Methamphetamine‐Induced Neurotoxicity in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1994, Journal of neurochemistry.

[16]  C. Marsden,et al.  Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.

[17]  R. S. Sohal,et al.  Relationship between mitochondrial superoxide and hydrogen peroxide production and longevity of mammalian species. , 1993, Free radical biology & medicine.

[18]  J. Bockaert,et al.  Nitric oxide, superoxide and peroxynitrite: Putative mediators of NMDA-induced cell death in cerebellar granule cells , 1993, Neuropharmacology.

[19]  Joseph Loscalzo,et al.  A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds , 1993, Nature.

[20]  J. Bockaert,et al.  NMDA-dependent superoxide production and neurotoxicity , 1993, Nature.

[21]  J. Brodkin,et al.  Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity , 1993, Pharmacology Biochemistry and Behavior.

[22]  T. Dawson,et al.  Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  C. Olanow,et al.  Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.

[24]  J. Clodfelter,et al.  Differing Neurotoxic Potencies of Methamphetamine, Mazindol, and Cocaine in Mesencephalic Cultures , 1993, Journal of neurochemistry.

[25]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[26]  M. Colado,et al.  Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine , 1993, British journal of pharmacology.

[27]  T. Koyama,et al.  Long-lasting decrease in dopamine uptake sites following repeated administration of methamphetamine in the rat striatum , 1993, Brain Research.

[28]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[29]  J. Cadet,et al.  The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynatic nigrostriatal markers in the rat , 1992, Brain Research.

[30]  C. Nathan,et al.  Nitric oxide as a secretory product of mammalian cells , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  G. Kreutzberg,et al.  Cytotoxicity of microglia , 1992, Journal of Neuroimmunology.

[32]  S. O'dell,et al.  MK‐801 protection against methamphetamine‐induced striatal dopamine terminal injury is associated with attenuated dopamine overflow , 1992, Synapse.

[33]  D. Ben-shachar,et al.  Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.

[34]  A. Heller,et al.  Survival of developing dopaminergic neurons in reaggregate tissue culture following treatment with methamphetamine , 1991, Neuroscience Letters.

[35]  J. Nash,et al.  Microdialysis studies on 3,4-methylenedioxyamphetamine and structurally related analogues. , 1991, European journal of pharmacology.

[36]  M. Naoi,et al.  Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. , 1991, Biochemical and biophysical research communications.

[37]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[38]  J. Cadet,et al.  Long-term behavioral and biochemical effects of 6-hydroxydopamine injections in rat caudate-putamen , 1991, Brain Research Bulletin.

[39]  B. Freeman,et al.  Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. , 1991, The Journal of biological chemistry.

[40]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[41]  Y. Agid,et al.  Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.

[42]  D. Dickson,et al.  Microglia in human disease, with an emphasis on acquired immune deficiency syndrome. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[43]  J. Cadet,et al.  Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats , 1991, Brain Research Bulletin.

[44]  P. Sonsalla,et al.  Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[45]  G. Jackson,et al.  Role of nerve growth factor in oxidant‐antioxidant balance and neuronal injury. I. Stimulation of hydrogen peroxide resistance , 1990, Journal of neuroscience research.

[46]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[47]  J. Cadet,et al.  Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain , 1989, Brain Research.

[48]  J. Cadet,et al.  Possible Involvement of Free Radicals in Neuroleptic‐Induced Movement Disorders Evidence from Treatment of Tardive Dyskinesia with Vitamin E , 1989, Annals of the New York Academy of Sciences.

[49]  G. C. Wagner,et al.  Methamphetamine-induced neuronal damage: A possible role for free radicals , 1989, Neuropharmacology.

[50]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[51]  T. Insel,et al.  3,4-Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. , 1989, The Journal of pharmacology and experimental therapeutics.

[52]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[53]  C. Marsden,et al.  Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease , 1989, Journal of neurochemistry.

[54]  W. Nicklas,et al.  Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. , 1989, Science.

[55]  J. Cadet,et al.  Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: Behavioral and biochemical evidence , 1989, Brain Research.

[56]  D. Giulian,et al.  Colony-stimulating factors as promoters of ameboid microglia , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[57]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[58]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[59]  B. Logan,et al.  Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. , 1988, European journal of pharmacology.

[60]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[61]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[62]  G. Hanson,et al.  Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. , 1988, The Journal of pharmacology and experimental therapeutics.

[63]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[64]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[65]  G. Hanson,et al.  The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. , 1986, European journal of pharmacology.

[66]  D Giulian,et al.  Characterization of ameboid microglia isolated from developing mammalian brain , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[67]  I. Fridovich.  Biological effects of the superoxide radical. , 1986, Archives of biochemistry and biophysics.

[68]  D. Hinshaw,et al.  Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. , 1986, The Journal of clinical investigation.

[69]  R. Duvoisin,et al.  Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity , 1985, Neuroscience Letters.

[70]  S. Kish,et al.  Glutathione peroxidase activity in Parkinson's disease brain , 1985, Neuroscience Letters.

[71]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain , 1985, Brain Research.

[72]  R. S. Burns,et al.  Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.

[73]  L. Seiden,et al.  Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine , 1984, Pharmacology Biochemistry and Behavior.

[74]  R. Duvoisin,et al.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. , 1984, Science.

[75]  K. Chiba,et al.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.

[76]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[77]  I. Mavelli,et al.  Superoxide dismutase, glutathione peroxidase and catalase in developing rat brain. , 1982, The Biochemical journal.

[78]  E. sanders-Bush,et al.  Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. , 1980, European journal of pharmacology.

[79]  J. Gibb,et al.  Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. , 1980, The Journal of pharmacology and experimental therapeutics.

[80]  L. Seiden,et al.  Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study , 1980, Brain Research.

[81]  L. Seiden,et al.  Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine , 1980, Brain Research.

[82]  Sanford P. Markey,et al.  Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.

[83]  D. Graham.  Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.

[84]  D. Graham,et al.  Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. , 1978, Molecular pharmacology.

[85]  C. Mytilineou,et al.  Destruction of sympathetic nerve terminals by 6-hydroxydopamine: protection by 1-phenyl-3-(2-thiazolyl)-2-thiourea, diethyldithiocarbamate, methimazole, cysteamine, ethanol and n-butanol. , 1976, The Journal of pharmacology and experimental therapeutics.

[86]  G. Cohen,et al.  The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. , 1974, The Journal of biological chemistry.

[87]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[88]  G. Stern,et al.  Tetrahydroisoquinoline Alkaloids: in vivo Metabolites of L-Dopa in Man , 1973, Nature.

[89]  S Fahn,et al.  Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. , 1971, Journal of the neurological sciences.

[90]  G. Breese,et al.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.

[91]  E. Roberts.  The synapse as a biochemical self--organizing micro-cybernetic unit. , 1966, Brain research.

[92]  M. Naoi,et al.  Dopamine-Derived Isoquinolines as Dopaminergic Neurotoxins and Oxidative Stress , 1995 .

[93]  H. Kolb,et al.  Nitric oxide: a pathogenetic factor in autoimmunity. , 1992, Immunology today.

[94]  C. J. Schmidt,et al.  Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. , 1987, The Journal of pharmacology and experimental therapeutics.